Phase 3 Clinical Protocol: Placebo‐Controlled, Double‐Blind, Parallel‐Group to Study Safety and Efficacy of NA‐831 in Combination with Lecanemab in Subjects with Early Alzheimer’s Disease
Lloyd Tran, Zung Vu Tran, Fern Vu · 2025
Read Phase 3 Clinical Protocol: Placebo‐Controlled, Double‐Blind, Parallel‐Group to Study Safety and Efficacy of NA‐831 in Combination with Lecanemab in Subjects with Early Alzheimer’s Disease by Lloyd Tran, Zung Vu Tran, Fern Vu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11714023.txt.
Description
Lloyd Tran, Zung Vu Tran, and Fern Vu lay out a Phase 3 trial plan in a 2025 conference paper. The plan pairs a test drug with an approved antibody in early Alzheimer's disease. The approved drug, lecanemab, clears amyloid but slows decline only a bit. The test drug, NA-831, passed early safety and effect checks.
The plan enrolls 600 adults, ages fifty to ninety, for an eighteen month core phase. People are split at random into groups: the test drug alone, the pair of drugs, or a dummy pill. No one knows who gets what while the core runs. An open phase follows where all can take the pair. The team will weigh thinking change and side effects, with a hope that the pair can use lower doses.
Catalog record
| CREATOR | Lloyd Tran, Zung Vu Tran, Fern Vu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |